Pharmacists of Uni Pharma Co., Ltd.. Wu Qianhua and Huang Junwei
Cai Yiqian, Commissioner of the Medical Department of Uni Pharma Co., Ltd.
Zhu Jiaying, medical examiner of Uni Pharma Co., Ltd.
Neuromyelitis optica (NMOSD) is a serious autoimmune inflammatory disease of the central nervous system. In the early stage, due to the lack of research on the disease, it is easy to be confused with multiple sclerosis, but the two are different diseases and have different treatments. If multiple sclerosis (MS) is treated in the same way as panoptic neuromyelitis, it may be harmful rather than effective. Episodes of panoptic neuromyelitis are severe and can recur and worsen with permanent damage, and if not properly managed, may eventually lead to death from respiratory failure. The pathology is known to be related to aquaporin 4 and can be confirmed by testing for aquaporin 4 antibody (AQP4-IgG). Immunosuppressive therapy is the main treatment, but there is no international consensus, and different countries will prioritize different recommendations due to the convenience of obtaining drugs or therapies. This article briefly describes the development of panoptic neuromyelitis and the treatment strategies recommended by different international experts for the reference of pharmacists.
Keywords: Neuromyelitis optica, Multiple Sclerosis, NMOSD, NMO-IgG, AQP4 antibody, MOG antibody
Journal of Pharmaceutical Sciences, Vol. 33, No. 4
THE JOURNAL OF TAIWAN PHARMACY Vol.33 No.4
